TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03287089

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrofurantoin 100 MG
Description: Patients will receive nitrofurantoin 100mg twice daily by mouth for 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Matching placebo
Study: NCT04468100

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tigerase®
Description: 2.5 mL (2.5 mg) dornase alfa nebulized once daily for 168 (+/-7) days
Study: NCT04785872

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: NEUMAN SYSTEMS MODEL BASED NURSING APPROACH
Study: NCT00681343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Description: Induction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Campath-1H
Description: Induction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclizumab
Description: Induction
Study: NCT01506388

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: foley catheter
Description: foley 14 catheter intracervical plus vaginal IMN 40 mg evry 6 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: misoprostol 50 Ug , vaginally every 4-6 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaginal IMN
Description: IMN vaginal 40 mg every 4-6 hours
Study: NCT00613808

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitric Oxide 200ppm Group B
Description: 200 ppm, 8hrs / day for 6 weeks
Study: NCT00089804

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: abetimus sodium (LJP 394) and/or placebo solution
Description: 300 mg (50 mg/mL)abetimus sodium (three 2 mL vials of of abetimus sodium plus six 2 mL vials of normal saline) administered i.v. (in the vien) weekly for 52 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: abetimus sodium (LJP 394)
Description: 900 mg (50 mg/mL) abetimus sodium (nine 2 mL vials) administered i.v. (in the vien) weekly for 52 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Phosphate-buffered saline
Description: A volume of 18 mL (nine 2 mL vials of normal saline) of identically appearing placebo (phosphate-buffered saline) administered i.v. (in the vien) weekly for 52 weeks
Study: NCT04468100

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pulmozyme®
Description: 2.5 mL (2.5 mg) dornase alfa nebulized once daily for 168 (+/-7) days
Study: NCT04783402

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: e-OTCAT program
Description: The e-OTCAT program consists of a combination of cognitive training in terms of attention, memory and processing speed; and adaptive training based on metacognition and cognitive-behavioral strategies (psycho-education, relaxation techniques training, stress management, energy conservation techniques, time management, etc.).~This program also includes homework exercises consisting of a handbook of paper-and-pencil exercises, a cognitive training mobile app, and the practice of strategies seen in adaptive training sessions.

Intervention type: OTHER
Group type: OTHER
Intervention: Educational handbook and standard care
Description: At the beginning of chemotherapy, the participants will receive an educational handbook containing information about most frequent side-effects of cancer and cancer treatments, plus standard care.
Study: NCT00268450

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Before surgery: given as a 15mg/kg IV over 90 minutes every 21 days for 4 cycles~After surgery: given as a 15mg/kg IV over 90 minutes every 21 days for 3 cycles
Study: NCT03666494

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine Hydrochloride
Description: As part of anesthetic induction, the addition of ketamine hydrochloride 0.5mg/kg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: As part of the patient's anesthetic induction, they will receive propofol.
Study: NCT04632589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan Potassium
Description: subjects ingest 50mg losartan potassium tablet daily for 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: subjects ingest placebo tablet daily for 6 weeks
Study: NCT03954080

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraspinal-optimal stim therapy
Description: During the trial, percutaneous lead(s) will be implanted, following standard clinical practices, in the posterior epidural space with the final lead position located in the optimal area to provide pain relief by stimulating neural tissue in order to create paresthesia(s) only on the painful dermatome(s). During Intraspinal-Optimal Stim, a set of electrodes in the stimulation lead(s) will deliver a charge-balanced, pulsed electrical signal with stimulation parameters (frequency, pulse width, and amplitude) within the FDA approved specifications of the commercially available external neurostimulator. These will be adjusted to produce paresthesia coverage of the painful area. Patients that will report equal or greater than 50% reduction in pain, relative to baseline pain, may undergo permanent implantation of a commercially available neurostimulator (INS). This will require a surgical intervention to implant stimulation leads, INS and anchoring hardware followed by therapy programming.
Study: NCT01035489

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CRT in heart failure; Right ventricular apex v.s. high posterior septum
Description: RV lead is randomized to either apex or high posterior septum

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CRT in heart failure; Right ventricular apex v.s. high posterior septum
Description: RV lead is randomized to either apex or high posterior septum
Study: NCT04385459

Intervention type: OTHER
Intervention: Coronary artery disease
Description: Exposure
Study: NCT00596752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprostadil
Description: * Active Substance: Prostaglandin E1~* Pharmaceutical Form: solution for infusion~* Concentration: 40 μg b.d.~* Route of Administration: intravenous infusion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * Active Substance: Lactose~* Pharmaceutical Form: solution for infusion~* Concentration: 40 μg b.d.~* Route of Administration: intravenous infusion
Study: NCT02745834

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gait analysis
Description: Gait will be analysed while participants will walk on a treadmill at different self selected speeds, using the OPTOGait system. Spatiotemporal measures are collected without the use of any markers.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gait analysis
Description: Gait will be analysed while participants will walk on a treadmill at different self selected speeds, using the OPTOGait system. Spatiotemporal measures are collected without the use of any markers.
Study: NCT03206801

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Kidney transplant biopsy
Description: Elevated urine CXCL10 will trigger a study biopsy in patients randomized to the intervention arm. Subclinical rejection will be treated per protocol.
Study: NCT02843672

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Triple Weil´s Osteotomy
Description: A 10mm longitudinal incision is made with a No.15 blade in the second intermetatarsal space immediately behind the dorsal interdigital fold, parallel to the extensor tendon. An intra-articular osteotomy in the metatarsal head is performed angled 45º relative to the long axis of the metatarsal and in a dorsal-distal to proximal-plantar direction. A second osteotomy is performed perpendicular to the metatarsal shaft,.The osteotomy is fastened with a 2.0mm snap-off screw.~Once all the osteotomies are completed, the incisions are closed with a 2/0 monofilament suture.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Distal metatarsal minimally invasive osteotomy
Description: A 5mm longitudinal incision is made with a MIS blade No.64 in the intermetatarsal space immediately behind the dorsal interdigital fold, parallel to the extensor tendon. Under fluoroscopy vision, an extra-articular osteotomy in the metatarsal neck is performed angled 45º relative to the long axis of the metatarsal and in a dorsal-distal to proximal-plantar direction. The osteotomies scheduled preoperatively are performed, repeating the same procedure for each ray needing an osteotomy. Once all are completed, the incisions are closed with a 4/0 monofilament suture.
Study: NCT01629173

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dynamic impression insole
Description: We sequentially padded (1)a 6.5-mm thick P-cell (21 Shore A hardness, Acor orthopedic Inc. Cleveland, Ohio, USA), and (2)a piece of metatarsal pad and arch support made of Ethylene Vinyl Acetate (EVA) (40 Shore A hardness, Schein orthopadie service KG. Remscheid, Germany) to the bottom of the impressed 9-mm thick plastazote (15 Shore A hardness, Schein orthopadie service KG. Remscheid, Germany) with double-sided adhesive tape in the forefoot region and just proximal to the first, second, and third metatarsal head region. We additionally padded a 2-mm thick Multiform (30 Shore A hardness, Schein orthopadie service KG. Remscheid, Germany) on the top of the impressed insole with double-sided adhesive tape.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Custom molded insole
Description: The custom molded insole was made by sequentially padded Multiform (30 Shore A hardness, Schein orthopadie service KG. Remscheid, Germany), P-cell (21 Shore A hardness, Acor orthopedic Inc. Cleveland, Ohio, USA), Ethylene Vinyl Acetate (EVA)(40 Shore A hardness, Schein orthopadie service KG. Remscheid, Germany), and cork (50 Shore A hardness, Schein orthopadie service KG. Remscheid, Germany) on the positive plaster cast impressed by an impression box while holding the subtalar joint at a neutral position.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 9-mm uncompressed Plastazote
Description: We used 9-mm flat Plastazote(15 Shore A hardness, Schein orthopadie service KG. Remscheid, Germany) as an insole

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 7-mm Ethylene Vinyl Acetate (EVA)
Description: We used 7-mm flat Ethylene Vinyl Acetate (EVA) (40 Shore A hardness, Schein orthopadie service KG. Remscheid, Germany) as an insole
Study: NCT01651871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-555739 Dose 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-555739 Dose 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-555739 Dose 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetirizine HCl Dose 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetirizine HCl Dose 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetirizine HCl Dose 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-555739 placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-555739 placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: S-555739 placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetirizine HCl placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cetirizine HCl placebo
Study: NCT01415401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brinzolamide 1% / timolol 0.5% maleate fixed combination
Study: NCT04468841

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: cfDNA testing
Description: peripheral blood samples collected before initiation of standard therapy, after 2 cycles of therapy, at the completion of 6-8 cycles of induction therapy, and then every 6 months for a total of 2 years from the initiation of therapy using a cfDNA assay. For retrospective patients, blood samples will be collected once.
Study: NCT03666494

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: As part of the patient's anesthetic induction, they will receive propofol.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: As part of the patient's anesthetic induction, they will receive fentanyl.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: As part of the patient's anesthetic induction, they will receive fentanyl.
Study: NCT02427542

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CBT for Depersonalization/Derealization
Description: In addition to treatment as usual, six sessions of Cognitive Behavioural Therapy for Depersonalization/Derealisation covering psychoeducation, formulation, coping strategies.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Treatment as usual
Description: Treatment as usual - in most cases case management/care coordination and may include medication
Study: NCT02545699

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: G-EYE™ Colonoscopy
Description: G-EYE™ Colonoscopy
Study: NCT04468841

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: cfDNA testing
Description: peripheral blood samples collected before initiation of standard therapy, after 2 cycles of therapy, at the completion of 6-8 cycles of induction therapy, and then every 6 months for a total of 2 years from the initiation of therapy using a cfDNA assay. For retrospective patients, blood samples will be collected once.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sample of saliva or fingernail clipping
Description: collected in clinic one time

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sample of saliva or fingernail clipping
Description: collected in clinic one time
Study: NCT02545699

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Colonoscopy
Description: Standard Colonoscopy
Study: NCT00008216

Intervention type: PROCEDURE
Intervention: Peripheral Blood Stem Cell Transplantation
Study: NCT04197856

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care encouraging family-mediated disclosure of hereditary cancer risk
Description: At counseling, eligible at-risk relatives (who may benefit from disclosure of risk information) are listed on a specified protocol in collaboration between health care provider and the participant.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard care encouraging family-mediated disclosure of hereditary cancer risk
Description: At counseling, eligible at-risk relatives (who may benefit from disclosure of risk information) are listed on a specified protocol in collaboration between health care provider and the participant.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Offer of health-care assisted disclosure by sending direct letters to at-risk relatives
Description: The participant is offered that the health care provider at the cancer genetic unit mail a direct letter with personalized family risk information to all at-risk relatives that participant approve contact with.
Study: NCT02611193

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manipulative treatment
Description: Manipulative treatment as described by the GBMOIM (Grupo Barcelona de Medicina Ortopédica y Manual) will be perform with extension of the transverse carpal ligament maneuver and fascia release maneuver

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Simulated manipulative treatment
Description: Simulated Manipulative Treatment
Study: NCT00714064

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 23vPPV, dTpa (Pneumovax, Boostrix)
Description: Group A will receive 23vPPV during 3rd trimester and dTpa at delivery
Study: NCT00118937

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Tablet Metformin 500 mg, Dosage: 1000 mg two times daily (2000 mg total daily dose).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo.
Description: Tablet Placebo (corresponding to 500 mg metformin). Dosage: 1 tablet per day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo.
Description: Tablet Placebo (corresponding to 500 mg metformin). Dosage: 2 tablets two times daily.
Study: NCT03425500

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bridging Rotator Cuff Reconstruction
Description: Bridging Rotator Cuff Reconstruction of massive rotator cuff tear using a GRAFTJACKET™ allograft

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Superior Capsular Reconstruction
Description: Superior Capsular Reconstruction of massive rotator cuff tear

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GRAFTJACKET™ allograft
Description: The acellular human dermal allograft in used in the bridging rotator cuff reconstruction
Study: NCT00714064

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 23vPPV, dTpa (Pneumovax, Boostrix)
Description: Group B will receive 23vPPV at delivery and dTpa 7 months following delivery
Study: NCT03363100

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital health Partnership program
Description: The program pairs patients with their own certified diabetes educator coach who will guide the patient through a personalized program that leverages a proven educational curriculum combined with proven patient engagement methods.
Study: NCT04468841

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: pre-treatment test specimen
Description: From bone marrow, blood, lymph node, or alternate site to identify tumor-specific mutations. For retrospective patients initial tumor tissue (if available).
Study: NCT02416947

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 0 g SCF
Description: 0 grams of SCF will be administered daily in two equal doses in the form of a muffin and a drink.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 10g SCF
Description: 10 grams of SCF will be administered daily in two equal doses in the form of a muffin and a drink.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 20g SCF
Description: 20 grams of SCF will be administered daily in two equal doses in the form of a muffin and a drink.
Study: NCT04468841

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: pre-treatment test specimen
Description: From bone marrow, blood, lymph node, or alternate site to identify tumor-specific mutations. For retrospective patients initial tumor tissue (if available).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/CT, CT, or MRI testing
Description: PET/CT scans are required at baseline and at the patient's end-of-treatment visit. The other standard-of-care scan timepoints can be performed using PET/CT, dedicated CT, or MRI per the treating investigator's discretion.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/CT, CT, or MRI testing
Description: PET/CT scans are required at baseline and at the patient's end-of-treatment visit. The other standard-of-care scan timepoints can be performed using PET/CT, dedicated CT, or MRI per the treating investigator's discretion.
Study: NCT00098579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alvocidib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV
Study: NCT00714064

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: 23vPPV, dTpa (Pneumovax, Boostrix)
Description: Group C will receive dTpa at delivery and 23vPPV 7 months following delivery
Study: NCT03468348

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Description: patients scheduled for mastectomy and axillary evacuation for cancer breast will receive orally, 2 hours before the operation either, placebo capsule, duloxetine 30 mg,duloxetine 60 mg or duloxetine 90 mg capsule.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Description: patients scheduled for mastectomy and axillary evacuation for cancer breast will receive orally, 2 hours before the operation either, placebo capsule, duloxetine 30 mg,duloxetine 60 mg or duloxetine 90 mg capsule.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Description: patients scheduled for mastectomy and axillary evacuation for cancer breast will receive orally, 2 hours before the operation either, placebo capsule, duloxetine 30 mg,duloxetine 60 mg or duloxetine 90 mg capsule.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Duloxetine
Description: patients scheduled for mastectomy and axillary evacuation for cancer breast will receive orally, 2 hours before the operation either, placebo capsule, duloxetine 30 mg,duloxetine 60 mg or duloxetine 90 mg capsule.
Study: NCT02212275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethophan
Description: A single age and weight appropriate dose of over the counter Delsym Cough Syrup containing only DXM as an active ingredient.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dextromethophan
Description: A single age and weight appropriate dose of over the counter Delsym Cough Syrup containing only DXM as an active ingredient.
Study: NCT01123044

Intervention type: BIOLOGICAL
Group type: NO_INTERVENTION
Intervention: conservative
Description: Undergo autologous transplantation of limbal epithelial cells cultured on amniotic membrane

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: conservative
Description: Undergo autologous transplantation of limbal epithelial cells cultured on amniotic membrane
Study: NCT02778893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conmana
Description: 125mg three times a day (TID) continuously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: 100mg one a day（QD）at night continuously,If can tolerance after 1 weeks to add to 200mg;
Study: NCT05140109

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Arm 1: Cognitive-dissonance based program
Description: The first four sessions focus on body image and the last four sessions on eating behavior.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Arm 2: Mindfulness-based program
Description: The sessions focus on different contents as body image, eating behavior and emotion regulation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Arm 3: Person-centered program
Description: The sessions are not structured. Participants can bring any subject they need to talk.